GlassScriptPhysician profile
Mitchell Heston Kaufman
NPI 1164536553
$5,227.52
in general payments reported to CMS, 2019-2025
38 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $310 · 2021: $1,800 · 2022: $1,181 · 2023: $931 · 2024: $486 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,216.37 | 2021-2025 | Vumerity, Tysabri, Tysabri |
| Teva Pharmaceuticals USA, INC. | $499.98 | 2019-2024 | Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $314.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $307.18 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $257.20 | 2021-2024 | Ingrezza |
| Emd Serono, INC. | $255.16 | 2020-2023 | |
| Lundbeck LLC | $223.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $185.06 | 2021 | |
| Jazz Pharmaceuticals INC. | $182.93 | 2021-2024 | |
| Eisai INC. | $175.60 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $169.09 | 2019-2020 | |
| Acorda Therapeutics, INC | $143.13 | 2021-2023 | Inbrija, Ampyra |
| Amneal Pharmaceuticals LLC | $142.58 | 2022-2025 | Crexont |
| Sk Life Science, INC. | $124.99 | 2023 | Xcopri |
| Amgen INC. | $124.98 | 2024 | Uplizna |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $124.93 | 2021 | |
| Neurelis, INC. | $122.45 | 2022 | |
| Genzyme Corporation | $80.09 | 2021 | |
| Harmony Biosciences LLC | $70.19 | 2022 | |
| Kyowa Kirin, INC. | $67.02 | 2022 | |
| Abbvie INC. | $58.38 | 2024 | |
| Merz Pharmaceuticals, LLC | $55.05 | 2022-2023 | Xeomin |
| Axsome Therapeutics, INC. | $44.34 | 2024 | Sunosi |
| Ucb, INC. | $38.48 | 2022-2023 | Briviact |
| Argenx US, INC. | $29.83 | 2024 | Vyvgart |
| Scilex Pharmaceuticals INC. | $29.00 | 2022 | |
| Adamas Pharmaceuticals, INC. | $27.27 | 2021 | |
| Tanabe Pharma America, INC. | $20.92 | 2021 | |
| Banner Life Sciences, LLC | $18.71 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $16.67 | 2023 | Fycompa |
| Csl Behring | $14.33 | 2021 | |
| Genentech USA, INC. | $13.78 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.42 | 2021 | |
| Lilly USA, LLC | $13.23 | 2022 | |
| Boston Scientific Corporation | $12.28 | 2021 | |
| Avanir Pharmaceuticals, INC. | $11.94 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.37 | 2021 | |
| Bausch Health US, LLC | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.